Repeated COVID vaccines enhance mucosal immunity against the virus

People who received multiple doses of mRNA vaccines showed more neutralizing antibodies in nasal secretions

Ghent, October 24, 2024 – During the COVID pandemic, many of us have received multiple mRNA vaccines. New work by researchers at the VIB-UGent Center for Inflammation Research, Ghent University, and University Hospital Ghent, among others, has found that such repeated vaccinations lead to the presence of mucosal antibodies, for example, inside the nose. Their work appears in Science Translational Medicine.

Protective booster shots

Part of the global response strategy against the COVID pandemic involves the administration of booster shots, or ‘vaccine updates’ to ensure protection against new variants of the SARS-CoV-2 virus.

The researchers set out to investigate the effects of multiple mRNA vaccines on mucosal immunity, referring to mucous membranes such as the ones on the inside of our noses. Specifically, the research involved a cohort of 183 participants who were sampled at multiple time points after primary and booster vaccinations.

PhD student Jozefien Declercq (VIB-UGent) explains: ​ “We found that individuals who received multiple doses of mRNA vaccines exhibited a marked increase in neutralizing antibodies in nasal secretions, which are essential for blocking viral entry. Not only that, but the immune responses generated by mRNA vaccines may persist longer than previously thought, which provides hope for sustained protection against emerging variants of the virus.”

From the blood to the nose

How do the antibodies produced in response to the vaccine get to the nose, though?

Prof. Dr. Stijn Vanhee (VIB-UGent), co-senior author of the study, explains. “Using a mouse model, we discovered that most mucosal neutralizing antibodies were of systemic origin, with antibodies circulating in the blood migrating to the respiratory mucosa in the nose, suggesting that repeated vaccination stimulates systemic antibody production that can reach mucosal membranes.”

The findings suggest that repeated vaccinations not only bolster systemic immunity but also enhance mucosal antibody responses, providing a more robust defense against the virus.

Prof. Dr. Linos Vandekerckhove (Ghent University), co-senior author of the study, emphasizes the critical role of mucosal immunity in the fight against COVID-19. "Our study provides compelling evidence that repeated mRNA vaccinations can improve mucosal antibody responses, or stimulate pre-existing infection induced mucosal responses, which are vital for preventing infection at the entry points of the virus. This could have profound implications for public health strategies moving forward, especially as we face new variants of concern.”
Jozefien Declercq, Stijn Vanhee, and Linos Vandekerckhove.

Publication

Repeated COVID-19 mRNA-based vaccination contributes to SARS-CoV-2 neutralizing antibody responses in the mucosa. Declercq et al. Science Translational Medicine, 2024.

Funding

This study was funded by Research Foundation Flanders (FWO), the European Research Council (ERC), Ghent University, and VIB’s Grand Challenges program.


Gunnar De Winter

Gunnar De Winter

Science Communications Expert, VIB

Share

Latest stories

Website preview
Blocking lipid production in healthy lung cells can reduce lung metastasis
Leuven, 17 March 2026 - Scientists from the VIB–KU Leuven Center for Cancer Biology, in collaboration with the Francis Crick Institute, have discovered how cancer cells can exploit healthy lung cells to support metastatic tumor growth in the lungs. In two complementary studies published in Nature Cell Biology and Cancer Discovery, they show that tumors use lipids produced by lung cells as signals, and that decreasing the lipid production of lung cells can decrease metastasis. The findings point to new therapeutic strategies that target lung cell lipid production, rather than cancer cells themselves, which may also help refine patient selection for ongoing clinical trials targeting this pathway.
press.vib.be
Website preview
Researchers identify major genetic risk factor for rare form of dementia
Antwerp, 12 March 2026 - Researchers at VIB and Antwerp University have identified a major genetic risk factor for a rare form of frontotemporal dementia. The discovery, published today in Nature Genetics, provides a biological entry point for a disease subtype that has been difficult to study. It could not only help to improve diagnosis and patient stratification, but also opens up new avenues toward targeted treatments.
press.vib.be
Website preview
Protealis Announces Regulatory Approval of its First Biological Solution MagNfixTM and Launch of Five New Soybean Varieties
Ghent (Belgium), 11 March 2026 – Protealis, the European specialist in non-GMO legume seeds and seed technologies, today announces several milestones that significantly strengthen its position in a fast-growing European soybean market. The company has obtained European regulatory approval from EFCI1 (EU Fertilising Products Regulation (FPR) 2019/1009) for MagNfix™, its first biological solution, which is a proprietary soybean inoculant seed coating that is designed to support higher soybean yield and protein content. In addition, Protealis has secured the registration of five new soybean varieties across four European countries. This includes the introduction of two new maturity group (MG) 000 soybean varieties in Poland, the registration of its first maturity group 0000 ultra-early soybean variety in France, and a new soy variety registration for Belgium. In Germany, Protealis received registration for its second 00 MG soybean variety suited for the regions in southern Germany...
press.vib.be

About VIB Press

VIB is an independent research institute that translates insights in biology into impactful innovations for society. Collaborating with the five Flemish universities, it conducts research in plant biology, cancer, neuroscience, microbiology, inflammatory diseases, artificial intelligence and more. VIB connects science with entrepreneurship and stimulates the growth of the Flemish biotech ecosystem. The institute contributes to solutions for societal challenges such as new methods for diagnostics and treatments, as well as innovations for agriculture. 

Learn more at www.vib.be.

Contact

Suzanne Tassierstraat 1 9052 Zwijnaarde

+32 9 244 66 11

press@vib.be

vib.be